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Hongxia Wang1,7, Xiaoyan Tan6, Jingyuan Du1, Susu Jin1, Kecheng Huang6, Fanrong Jiang8, Shun Zhang2, 
Nanhong Zheng1, Yaoren Hu1, Ting Cai1,2,* and Guruprasad P. Aithal4,5,*
This study aimed to investigate whether specific medications used in the treatment chronic diseases affected either 
the development and/ or severity of coronavirus disease 2019 (COVID-19) in a cohort of 610 COVID-19 cases and 
48,667 population-based controls from Zhejiang, China. Using a cohort of 578 COVID-19 cases and 48,667 population-
based controls from Zhejiang, China, we tested the role of usage of cardiovascular, antidiabetic, and other medications 
on risk and severity of COVID-19. Analyses were adjusted for age, sex, and body mass index and for presence of 
relevant comorbidities. Individuals with hypertension taking calcium channel blockers had significantly increased risk 
(odds ratio (OR) = 1.73, 95% confidence interval (CI) 1.2–2.3) of manifesting symptoms of COVID-19, whereas those 
taking angiotensin receptor blockers and diuretics had significantly lower disease risk (OR = 0.22, 95% CI 0.15–0.30 
and OR = 0.30, 95% CI 0.19–0.58, respectively). Among those with type 2 diabetes, dipeptidyl peptidase-4 inhibitors 
(OR = 6.02, 95% CI 2.3–15.5) and insulin (OR = 2.71, 95% CI 1.6–5.5) were more and glucosidase inhibitors were 
less prevalent (OR = 0.11, 95% CI 0.1–0.3) among with patients with COVID-19. Drugs used in the treatment of 
hypertension and diabetes influence the risk of development of COVID-19, but, not its severity.
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE 
TOPIC?
 Cardiovascular disease and diabetes have been highlighted as 
comorbidities contributing to a more severe form of coronavirus 
disease 2019 (COVID-19) and medication to treat them may 
also influence the risk of COVID-19 and its clinical outcomes.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Does specific medications used in the treatment of chronic 
diseases influence the risk for the susceptibility to severe acute 
respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection 
of severity of COVID-19?
WHAT DOES THIS STUDY ADD TO OUR KNOW- 
LEDGE?
 The study confirms that higher body mass index, diabetes, 
and cardiovascular,and cerebrovascular disease as independent 
risk factors for the development of COVID-19. Angiotensin 
receptor blockers (ARBs) and diuretics were associated with 
reduced risk and calcium channel blockers with increased risk 
of developing COVID-19. Among those with type 2 diabetes 
(T2D), dipeptidyl peptidase-4 and insulin were associated 
with increased and glucosidase inhibitors with reduced risk 
development of COVID-19. None of the antihypertensive or 
antidiabetic drugs were associated with increased risk of severe 
or critical form of the infection. Drugs used in the treatment 
of hypertension and diabetes influence the risk of develop-
ment of COVID-19, but are not associated with severity of the 
disease.
HOW MIGHT THIS CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE?
 Findings from the current large case-control study con-
firmed no evidence to alter ARB or angiotensin-converting en-
zyme inhibitor therapy in the context of COVID-19 severity in 
clinical practice. Hypertension significantly increases the risk 
of severe or critical SARS-CoV-2 infection indicating that care-
fully controlled blood pressure should be a priority to reduce the 
healthcare burden of COVID-19.
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The pandemic of coronavirus disease 2019 (COVID-19) caused 
by a new zoonotic coronary virus, severe acute respiratory syn-
drome-coronavirus 2 (SARS-CoV-2), has affected over 8.5 million 
people and caused over 450,000 deaths across the world as of June 
21, 20201 having a profound impact on health services and public 
health. The clinical spectrum of SARS-CoV-2 infection appears 
to be wide, encompassing asymptomatic infection in a minimum 
of 5%, mild upper respiratory tract illness with fever, fatigue, 
cough with or without sputum production in 81%, to more severe 
viral pneumonia in 14% with ground-glass opacity computed to-
mography (CT) of the chest leading to critical illness in 5% asso-
ciated with respiratory failure, septic shock, and/ or multi-organ 
failure.2 Case-fatality rate ranges from 0.4% to 2.9% on average 
between different regions.2
Large descriptive studies have reported T2D in 7.4–9.6% of pa-
tients with COVID-19 and hypertension in 15% as 2 of the most 
prevalent comorbid conditions.3–5 Moreover, diabetes (16.2%) 
and hypertension (23.7%) are highly prevalent among those with 
severe manifestations.3 Of the patients admitted to the intensive 
care unit, 22% of those who died had diabetes.6
SARS-CoV-2 virus binds ACE27,8 in humans, ACE2 is ex-
pressed broadly including epithelial cells of the lungs, intestines, 
kidneys, heart, and blood vessels.9 The virus downregulates the 
ACE2 protein expression in a replication-dependent manner10 
resulting in loss of ACE2 function. Whether variation in ACE2 
expression contributes to the virulence in the current pandemic 
of COVID-19 is still unclear. There is an ongoing debate as to 
whether and how the interaction among the virus, hypertension, 
and ACE2 may influence the manifestations of COVID-19.11–13 
Concerns have been raised that angiotensin converting enzyme in-
hibitors (ACEIs), angiotensin II type 1 receptor blockers (ARBs), 
and thiazolidinediones often prescribed in patients with diabetes, 
hypertension, and cardiac disease may increase the risk of COVID-
19 and its clinical outcomes.11,12,14 In contrast, ACE2 is a counter 
regulatory enzyme that degrades angiotensin II, hence, reduc-
ing its effect on vasoconstriction, sodium retention, and fibrosis. 
Therefore, trials of losartan as a treatment for COVID-19 are un-
derway enrolling patients who have not previously received treat-
ment with ACEIs or ARBs.15 In addition, dipeptidyl peptidase-4 
(DPP4), the receptor for Middle East respiratory syndrome-re-
lated coronavirus, has been shown to have similar expression pro-
file to ACE2 in the lungs.16 DPP4 inhibitors are commonly used 
in the treatment of T2D.
We have investigated whether any of the medications for chronic 
conditions, in particular antihypertensive and antidiabetic medica-
tions, affected either the development and/ or severity of COVID-
19 using a multicenter cohort of 578 patients with common, severe, 
or critical forms of COVID-19 and 48,667 population-based con-
trol subjects from Zhejiang Province, China.
PATIENTS AND METHODS
The study protocol conformed to the ethical guidelines of the 1975 
Declaration of Helsinki. The local ethics committees of all hospitals 
approved the retrospective study of cohorts with COVID-19. The re-
quirement for written consent was waived due to the retrospective and 
anonymous nature of this study.
Cohort of cases
Consecutive patients presenting to 14 hospitals in Zhejiang 
Province, China (see collaborators), between January 10, 2020, 
and February 28, 2020, and confirmed diagnosis of COVID-19 
infection were included (Figure 1). The diagnosis of COVID-19 
was made in accordance with the Guidelines for the Diagnosis 
and Treatment of New Coronavirus Pneumonia (fifth edition) 
formulated by the National Health Commission of the People’s 
Republic of China.17 A confirmed case of COVID-19 was defined 
as a positive result on real-time reverse-transcriptase polymerase 
chain reaction assay of nasal and pharyngeal swab specimens. 
Only laboratory-confirmed cases were included in the study. The 
Figure 1 Flow chart of recruitment paths for research study participants. COVID-19, coronavirus disease 2019.
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clinical data of all patients were collected from the electronic 
health records (EHRs). All patients were administered with an-
tiviral and supportive treatment, and prevention of complications 
based on their clinical condition.
Clinical categories
The severity of the disease was classified into four categories ac-
cording to the Guidelines for the Diagnosis and Treatment of 
New Coronavirus Pneumonia (fifth edition)17: (i) mild type: pa-
tients with mild clinical symptoms and no pulmonary changes 
on CT imaging, (ii) common type: patients with symptoms of 
fever and signs of respiratory infection, and having pneumonia 
changes on CT imaging, (iii) severe type: patients presenting with 
any one item of the following: (a) respiratory distress, respiratory 
rate ≥  30/min, (b) oxygen saturation of finger ≤  93% in resting 
condition, and (c) arterial partial pressure of oxygen/oxygen con-
centration ≤ 300 mmHg (1 mmHg = 0.133 kPa), or (iv) critical 
type: patients meeting any one of the following criteria: (a) respi-
ratory failure requiring mechanical ventilation, (b) shock, and (c) 
requiring intensive care unit admission requirement due to mul-
tiple organ failure. Because only 32 patients with mild cases were 
available and they would normally not be hospitalized, these were 
removed from the analysis (Figure 1).
Population-based control group
Detailed methods and data sources used to establish an EHR-
based general population-based cohort study in an eastern coastal 
area of China has been described previously.18 The control 
group used in the current study is from the general population 
from Gulin town, an area of Ningbo City, Zhejiang Province, 
China, which covers the catchment area of one of the hospitals 
from which one-quarter of the patients with COVID-19 for this 
study were recruited. Since 2004, all citizens are offered regular 
health screening in Gulin Health Center. Detailed medical his-
tory is recorded in the Electronic Medical Record System. Gulin 
town was selected as a center of the “Mega-Project for National 
Science and Technology Development” under the “13th Five-Year 
Plan of China” for liver diseases between 2017 and January 2021. 
We included all adult citizens who had detailed medical records 
established by 2019. A total of 48,667 adults from 60,984 reg-
istered populations who had EHRs were included in this study 
(Figure 1). The following data were collected: (i) age, (ii) sex, (iii) 
detailed medical history, including diabetes, hypertension, malig-
nancy, other severe diseases (congestive heart failure, severe neu-
rological diseases, and previous organ transplantation), (iv) details 
of prescription drugs used to treat these medical conditions, and 
(v) personal health parameters, including history of alcohol con-
sumption and smoking, as well as anthropometric measurements, 
including body weight, height, waist circumference, and arterial 
pressure, as well as (vi) laboratory parameters, including serol-
ogy for hepatitis B and C (HBsAg and anti-HCV). Individuals 
in the control cohort whose health records showed a diagnosis of 
COVID-19 (n = 3) were removed from the analysis (Figure 1).
Health information systems in Gulin include different admin-
istrative databases of general demographic characteristics, health 
check information, health insurance database, inpatient and 
outpatient EHRs, chronic disease management (diabetes, hyperten-
sion, malignancy, and myocardial infarction), and death certificates, 
and so on. These databases are inherently linked to each other by a 
unique and encoded identifier for each individual. The system was 
originally designed in 2006 to facilitate routine primary care services 
for local general practitioners. Since 2009, this regional system has 
covered nearly all health-related activities of residents within this 
region, from birth to death, including children, adolescents, preg-
nant women, adults, and elderly people. Now, 98% of permanent 
residents are covered by the national health insurance and have 
registered in the health information system with a valid healthcare 
identifier.
All the chronic diseases diagnosed by doctors in Gulin or outside 
Gulin will be reported to Ningbo Centers for Disease Control and 
Prevention (CDC) and rechecked by the Department of Chronic 
Disease Management of Gulin hospital. All the prescription med-
icines of chronic diseases listed above are recorded and regularly 
verified.
Use of medication. It is the role of the Department of Chronic 
Diseases within each community hospital in Zhejiang Province 
to update the prescriptions of chronic diseases, such as diabetes, 
hypertension, cardiovascular, cerebrovascular disease, and tumors 
regularly. From these data, we were able to run a database search, 
including for this study, individuals who were classified as taking 
a given medication if they had been given a prescription for a drug 
at least three times. For patients with COVID-19, the medication 
was included only if 3 or more 1-month prescriptions were filled 
before diagnosis of COVID-19, according to the patient’s records.
Statistical methods
Categorical variables were expressed as frequency and percentages. 
Continuous variables were expressed as mean and SDs. Logistic 
regressions were carried out either unadjusted or adjusting for age, 
sex, and body mass index (BMI). P < 0.05 was considered statisti-
cally significant.
RESULTS
The selection of the study population is illustrated in Figure 1. 
A total of 610 patients with COVID-19 were enrolled after ad-
mission from various centers in the Zhejiang Province (Figure 1). 
A population-based cohort from the Zhejiang Province consist-
ing of 48,667 adults with health records was used as controls. 
The descriptive characteristics, comorbidities, and use of medica-
tion prior to admission available in both cases and controls were 
compared (Table 1). We found that prevalence of T2D, higher 
BMI, presence of cardiovascular, or cerebrovascular disease were 
associated with (all increased in) the patients with COVID-19 
(Table 1). We then adjusted all factors for age, sex, and BMI. In 
the case of antihypertensives, we further adjusted for hyperten-
sion, in the case of medication used to treat diabetes, we adjusted 
for the presence of T2D.
All the disease conditions associated with COVID-19 remain 
statistically significantly associated after adjustment for age, sex, 
and BMI. There was no significant difference in the use of gluco-
corticoids between COVID-19 and the population-based controls 
ARTICLE
VOLUME 108 NUMBER 6 | December 2020 | www.cpt-journal.com1188
and a significantly higher use of statins among patients with 
COVID-19.
We found that among individuals with a diagnosis of hyperten-
sion there was no difference in the use of ACEIs or beta-blockers, 
but individuals with COVID-19 were significantly more likely to 
be on calcium channel blockers (CCBs) and less likely to be on di-
uretics and on ARBs.
We also found that after adjustment for demographics and pres-
ence of T2D the use of antidiabetic medications was significantly 
different in patients with T2D with COVID-19 than in those 
without and this is particularly striking for use of glycosidase inhib-
itors, which are significantly less prevalent among individuals with 
T2D infected with COVID-19, and insulin and DPP4 inhibitors, 
which are much more likely to be used by patients with T2D and 
COVID-19 (Table 1).
We compared these figures graphically between controls and 
different severity categories in Figure 2. We see that, although hy-
pertension in itself is not more prevalent in COVID-19 diagnosed 
individuals than controls, it is much more prevalent in severe and 
critical cases (Table 2, Figure 2a). T2D, male sex, and age over 65 
years all show a similar pattern in terms of increased prevalence 
with severity (Table 2, Figure 2a).
With regard to antidiabetic medications after adjusting for age, 
sex, BMI, and diabetes, glucosidase inhibitors are less prevalent 
among T2D affected individuals symptomatic for COVID-19 and 
DPP-inhibitors and insulin are much more prevalent among patients 
with COVID-19. We compared these values to those in COVID-19 
severity categories (Figure 2b and Table 3) and we find that there 
is no significant association between use of DPP-inhibitors and 
COVID-19 severity after adjustment for age, sex, and BMI, resulting 
in odds ratio (OR) = 0.32 (95% confidence interval (CI) 0.02–2.18, 
P = 0.31). For insulin, we observed a trend for higher use among the 
severe cases with OR = 2.63 (95% CI 0.80–9.07, P = 0.11), which, 
however, did not achieve statistical significance (Table 3).
We carried out a similar analysis with antihypertensive med-
ications. We found that comparing population-based controls 
Table 1 Comparison between COVID-19 cases and controls, showing univariate ORs from logistic regression, and ORs 




Adjusted for age, sex, BMI
95% CI P value 95% CI P value
n 48,667 578
sex M, n 23,506 (48.3%) 293 (50.7%) 1.10 0.93 1.29 0.25
Age, years, mean (SD) 49.96 (16.69) 49.18 (14.16) 1.00 0.99 1.00 0.273
BMI, kg/m2 mean (SD) 22.79 (2.86) 24.01 (3.43) 1.13 1.10 1.16 < 0.0001
Smoke, n 4,725 (9.7%) 53 (9.2%) 0.90 0.66 1.19 0.477 0.71 0.51 0.98 0.071
HBV, n 2,287 (4.7%) 32 (5.5%) 1.22 0.84 1.71 0.275 1.27 0.86 1.81 0.201
Diabetes, n 2,920 (6.1%) 57 (9.8%) 1.70 1.28 2.22 0.0001 1.53 1.15 2.11 0.004
Hypertension, n 9,855 (20.2%) 130 (22.4%) 1.18 0.97 1.43 0.084 1.01 0.76 1.31 0.851
Cardiovascular or 
 cerebrovascular disease n
622 (1.3%) 15 (2.6%) 2.16 1.25 3.45 0.002 2.26 1.22 3.76 0.006
Tumor, n 973 (2.0%) 10 (1.8%) 0.86 0.43 1.53 0.648 0.92 0.51 1.73 0.991
Glucocorticoids, n 326 (0.6%) 5 (0.8%) 1.29 0.46 2.82 0.568 1.17 0.41 2.73 0.717
ACEI, n 555 (1.1%) 5 (0.8%) 0.75 0.27 1.64 0.538 0.61a 0.23 1.51 0.362
ARB, n 7,485 (15.4%) 50 (8.7%) 0.56 0.41 0.73 < 0.0001 0.22a 0.15 0.30 < 0.0001
CCB, n 4,740 (9.7%) 84 (14.6%) 1.61 1.27 2.01 < 0.0001 1.73a 1.21 2.31 0.001
Diuretic, n 2,467 (5.1%) 12.31 (2.1%) 0.43 0.24 0.72 0.003 0.30a 0.19 0.58 < 0.0001
Beta-blockers, n 1,221.54 (2.5%) 15 (2.3%) 0.96 0.53 1.57 0.892 0.80a 0.42 1.47 0.468
Glycosidase inhibitors, n 2,019 (4.1%) 15 (2.6%) 0.66 0.38 1.05 0.104 0.11b 0.10 0.41 < 0.0001
Biguanides, n 1,445 (2.9%) 28 (4.9%) 1.64 1.09 2.37 0.010 1.00b 0.58 1.62 0.975
Insulin secretagogues, n 700 (1.4%) 16 (2.8%) 1.92 1.12 3.06 0.010 1.23b 0.72 2.29 0.395
Thiazolidinediones, n 394 (0.8%) 3 (0.5%) 0.64 0.16 1.68 0.446 0.36b 0.11 1.21 0.121
DPP4 inhibitors, n 486 (0.1%) 6 (0.9%) 9.22 3.54 19.82 < 0.0001 6.02b 2.30 15.51 < 0.0001
Insulin, n 701 (1.4%) 16 (2.8%) 3.29 1.86 5.34 < 0.0001 2.71b 1.57 5.51 0.0002
Statins, n 443 (0.9%) 15 (2.6%) 2.82 1.60 4.57 < 0.0001 2.50 1.48 4.21 0.001
Fibrates, n 63 (0.1%) 0 (0.0%) 0.05 0.00 30.12 0.417 0.03 0.00 29.26 0.339
Aspirin, n 673 (1.3%) 10 
(1.8%)
1.45 0.75 2.53 0.220 1.28 0.57 2.63 0.512
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; CI, confidence interval; 
COVID-19, coronavirus disease 2019; DPP4, dipeptidyl peptidase-4; HBV, hepatitis B virus; OR, odds ratio.
aThere were 134 patients with COVID-19 and with hypertension. bThere were 58 patients with COVID-19 and with type 2 diabetes. 
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to COVID-19 diagnosed individuals, use of ARBs and diuretics 
was significantly less prevalent in COVID-19 cases with hyper-
tension than among hypertensive controls, whereas use of CCBs 
was significantly more prevalent among COVID-19 cases than 
controls after adjustment for age, sex, and BMI (Table 1). No sig-
nificant difference in susceptibility or severity was seen with use of 
Figure 2 Distribution of population demographics and medication use in the control cohort and COVID-19 positive cohort. (a) Comparison of 
demographic and comorbidity distribution between coronavirus disease 2019 (COVID-19) positive individuals grouped according to severity 
compared with the control cohort. (b) Comparison of use of type 2 diabetes (T2D) prescribed medications across the COVID-19 severity range 
compared with the control cohort. Error bars represent 95% confidence interval (CI). (c) Comparison of use of antihypertensive (HTN) prescribed 
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ACEIs (Figure 2c, Table 3). In terms of severity, there was a trend 
for use of beta-blockers to be more prevalent in severe and critical 
cases than in mild and common cases. However, after adjustment 
for age, sex, and BMI, none of the antihypertensive medications 
was significantly associated with COVID-19 severity (Figure 2c, 
Table 3).
The only type of medications that remained associated with 
COVID-19 severity after adjustment for age, sex, and BMI were 
immunosuppressive drugs (glucocorticoids) with an OR  =  5.37 
(95% CI 0.88–41.15; Table 3).
DISCUSSION
Recent descriptive cohort studies have reported T2D in 7.4–9.6% 
of patients with COVID-19 and hypertension in 15% as 2 of the 
most prevalent chronic health conditions.3–5,19 Using a case-con-
trol design involving 610 patients with COVID-19 and well-char-
acterized 48,667 population-based controls from the South-east 
region of China, we have identified higher BMI, diabetes, and car-
diovascular, andcerebrovascular disease as independent risk fac-
tors for the development of COVID-19. We found the prevalence 
of hypertension to be slightly higher among patients (22.4%), but 
this was not statistically significant compared with its prevalence 
of 20.2% in the population-based control group. Furthermore, age 
(> 65 years), sex (male), and BMI were associated with the develop-
ment of severe disease in 128 of 610 of those with COVID-19. In 
addition, when adjusted for age, sex, and BMI, those with a history 
of hypertension have over 2-fold risk of developing the severe form 
of COVID-19.
The analysis of medications acting on the renin-angiotensin-al-
dosterone system demonstrates that patients with COVID-19 
were significantly less likely compared with population-based con-
trols to be taking ARBs (8.7% vs. 15.4%) and diuretics (2.1% vs. 
5.1%) prior to their presentation, after adjusting for covariates, 
such as age, sex, and BMI, as well as presence of hypertension. In 
contrast, CCBs were associated with increased risk of COVID-19. 
Although hypertension is clearly a risk factor for severity, we found 
that none of the antihypertensive medications were positively asso-
ciated with severity of the disease. In the case-control analysis, pa-
tients with T2D, treatment with DPP4 inhibitors, and insulin were 
associated with increased risk of COVID-19, whereas glucosidase 
inhibitor therapy was associated with reduced risk. It has been sug-
gested that DPP4 residues might interact with SARS-CoV-2 S1 
domain of the Spike protein, also targeted by other coronaviruses 
that enter the host cells through the functional receptor DPP4.20 
Table 2 Association among demographics, clinical presentation at admission, comorbidities, and use of medication and 
COVID-19 severity
Severity category 2 (common) 3 + 4 (severe + critical) Adj OR 
severe vs. 
not 95% CI P valuen 450 128
Sex, male n 207 (46%) 86 (67%) 2.40 1.59 3.65 < 0.0001
Age years mean (SD) 47.26 (13.53) 56 (14.29) 1.04 1.03 1.06 < 0.0001
BMI kg/m2 mean (SD) 23.63 (3.29) 25.38 (3.59) 1.15 1.09 1.23 < 0.0001
Clinical presentation
Fever, n 365.5 (81.3%) 109.9 (85.9%) 1.61 0.42 2.50 0.111
Cough, n 296.64 (65.9%) 102.98 (80.4%) 2.13 1.33 3.49 0.002
Digestive symptoms, n 52.02 (11.5%) 20 (15.6%) 1.42 0.80 2.44 0.220
Systolic BP mmHg, mean (SD) 131.65 (19.29) 133 (18.17) 0.97 0.95 1.30 0.011
Diastolic BP mmHg, mean (SD) 81.07 (10.85) 78.75 (10.08) 0.96 0.93 0.99 0.009
Respiratory rate, mean (SD) 19.42 (1.80) 20.86 (4.58) 1.22 1.08 1.33 0.002
Peak temperature C, mean (SD) 37.88 (0.77) 38.08 (0.85) 1.38 1.06 1.80 0.018
Days since disease onset, mean (SD) 6.15 (5.15) 6.57 (3.99) 1.01 0.97 1.01 0.637
Hospital length of stay, mean (SD) 19.31 (18.63) 21.18 (9.87) 1.00 1.00 1.01 0.363
Death, n 0 (0.00%) 4* (3.1%) 1,054.07 0.00 inf 0.350
Comorbidities
Smoke, n 31 (6.9%) 20 (15.6%) 0.88 0.45 1.74 0.728
Chronic liver disease, n 27 (6.0%) 6 (4.6%) 0.77 0.28 1.80 0.573
Diabetes, n 37 (8.2%) 21 (15.6%) 1.13 0.64 1.41 0.570
Hypertension, n 77 (17.1%) 57 (44.5%) 2.88 1.54 4.96 0.0007
CVD cerebrovascular, n 10 (2.2%) 6 (4.6%) 1.12 0.37 3.39 0.841
Cancer, n 6 (1.3%) 4 (3.1%) 1.38 0.42 7.18 0.284
Adj, adjusted; BMI, body mass index; BP, blood pressure; CI, confidence interval; COVID-19, coronavirus disease 2019; CVD, cardiovascular disease; OR, odds ratio.
ORs were derived by logistic regression severe (severe + critical) vs. not severe (common). P values adjusted for age, sex, and BMI, except those for age, sex, and BMI.
*, 3 deaths and 1 lung transplant.
[Correction added on 22 October 2020, after first online publication: The values under ’3 + 4 (severe + critical)’ column pertaining to number of death was 
corrected to ’4* (3.1%)’ and the * footnote was added.]
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In addition to its catalytic functions, DPP4 also has a role in im-
mune mechanisms and the inflammatory process,20 which may be 
influenced by DPP4 inhibitors. Treatment with insulin may also 
reflect the degree of insulin resistance, a well-established risk factor 
for COVID-19. Alpha glucosidase inhibitors improve glycemic 
control by acting on intestinal membrane-bound enzymes; their ef-
fect on the cellular entry of SARS CoV-221 is unclear. In contrast to 
their association with the development of COVID-19, none of the 
antidiabetic drugs were associated with the severe or critical form 
of the disease. To our knowledge, these associations of antidiabetic 
medications with COVID-19 infection have not been demon-
strated so far. The higher intake of antidiabetic medications might 
be linked to a longer duration or lower glycemic control and points 
to the role of metabolic inflammation in predisposing individuals 
to developing the more severe form of the disease.22
Among medications, corticosteroid intake at baseline were the 
only group that increased the risk of severity of COVID-19, but 
this affected only 2.1% of patients. In the study from OpenSAFELY 
collaborative, patients with asthma with recent oral steroid treat-
ment had 25% additional risk of in-hospital mortality.23 Although, 
in the latter study, oral steroid treatment was used as a marker of se-
verity, the effect on the disease outcome could be related to recent 
exposure to corticosteroids.
The concerns raised regarding the safety of ACEIs and ARBs in 
relation to COVID-19 are based on the hypothesis that medications 
acting on the renin-angiotensin-aldosterone system may raise the ex-
pression of ACE2, the postulated receptor for SARS-CoV-2.14,24–26 
The virus uses human ACE227 expressed in lung alveolar epithelial 
cells to trigger the key manifestations and complications of the in-
fection. ACE2 is involved in the hydrolysis of angiotensin I and II 
into inactive forms 1–9 and 1–7, respectively.15 Angiotensin 1–7 
act on the Mas receptor to play a protective role through vasodila-
tory and anti-inflammatory properties, hence, balancing the actions 
of angiotensin II on the type 1 receptor.14,15 Concerns regarding 
both ACEIs and ARBs have led to calls for discontinuation of these 
drugs both prophylactically and in those with suspected COVID-
19.15 In contrast, using a large longitudinal population-based con-
trol group and a multi-center cohort of COVID-19 cases, we have 
demonstrated that those on ARBs are significantly less likely (OR 
0.22, 95% CI 0.15–0.30) to develop COVID-19. Potential benefit 
Table 3 Association between the use of medication and COVID-19 severity
Severity category use  
of medication 2 (common)
3 + 4 
(severe + critical)
Adj OR severe 






























2.70 0.87 9.24 0.539









0.98 0.35 2.60 0.536









3.79 0.34 84.60 0.290














1.78 0.54 5.13 0.296





1.32 0.28 4.66 0.680
Adj., adjusted; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CI, confidence interval; COVID-
19, coronavirus disease 2019; DPP4, dipeptidyl peptidase-4; HBV, hepatitis B virus; OR, odds ratio.
ORs were derived by logistic regression severe (severe + critical) vs. not severe (common). P values adjusted for age, sex, and BMI.
a There were 134 patients with COVID-19 and hypertension. b There were 58 patients with COVID-19 with type 2 diabetes.
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from ARBs in this context may be related to the effect of SARS-
CoV-2, which once gaining entry through ACE2 into type II pneu-
mocyte downregulates ACE2 leading to unabated angiotensin II 
induced organ injury. In a mouse model, SARS-CoV-1 induced 
lung injury could be limited by renin-angiotensin-aldosterone sys-
tem blockade.28 Our analysis has not shown ACEIs to have an ef-
fect similar to ARBs, consistent with the observations that ACEIs 
currently in clinical use do not directly affect ACE2 activity.29 We 
are not aware of any population-based case-control studies thus far 
investigating risk factors increasing susceptibility to COVID-19, 
however, a systematic review30 found that ACEIs reduced the risk 
of pneumonia. In the latter study, the benefits of ACEI were sub-
stantially greater among Asian patients and these were attributed to 
a higher prevalence of ACE polymorphisms increasing the ACEI 
levels and kinin catabolism in this ethnic group.
Of 578 patients with COVID-19, 128 developed severe or crit-
ical forms of the disease, higher proportion of patients (42.8%) 
with common forms of the disease were on ARBs compared with 
severe/critical (35.1%) forms of the disease. However, neither 
ARBs nor ACEIs were significantly associated with the severity of 
COVID-19. A cohort study from Wuhan Province, demonstrated 
lower (3.7%) 28-day all-cause mortality among 188 patients with 
COVID-19 receiving ARBs or ACEIs in-hospital compared with 
9.8% among those who were not receiving these drugs.31 That 
study was not powered to evaluate the effect of ACEIs vs. ARBs. 
In addition, a lower proportion of patients with COVID-19 over-
all were on ARBs or ACEIs than expected32,33 raising the possi-
bility that concerns regarding these drugs at the beginning of the 
epidemic may have resulted in change in medication in patients on 
admission. In-hospital use of ACEIs has previously been shown to 
be associated with lower rate of ventilation and in-hospital mortal-
ity with viral pneumonias.34
Our case-control analysis showed that those taking CCBs had 
significantly increased risk (OR 1.73, 95% CI 1.2–2.3) of mani-
festing symptoms of COVID-19. Two recent studies have shown 
consistent findings regarding the association between CCBs and 
increased risk of COVID-19 associated symptoms.35,36 The mech-
anisms underlying these findings are unclear as there is no evidence 
that CCBs alter ACE2 expression. One study including 4,792 pa-
tients hospitalized with pneumonia (bacterial and viral) showed 
an increased incidence of major cardiovascular events among those 
who were on CCBs, beta-blockers, or corticosteroids.37 Impaired 
induction of anti-viral type 1 interferon response to a range of 
respiratory viruses has been well-described in association with 
corticosteroids and may also apply in the context of COVID-19, 
explaining the association of these drugs with the severity of infec-
tion in our cohort.38,39
Hypertension was a strong risk factor for the development of the 
severe and critical forms of COVID-19 independently of antihyper-
tensive therapy. This may be related to higher levels of endothelin 
in patients with hypertension and its effect on innate immune re-
sponse. There is strong evidence that the innate immune response is 
key in the development of severe COVID-19.40 Recent data suggest 
that macrophages contribute to, and protect from, hypertension 
and that macrophage depletion augments the chronic hypertensive 
response to endothelin-1 (ET-1).41 High levels of ET-1 are linked 
to lung damage in HIV infection.42 It is thus possible that arterial 
hypertension, which is linked to higher levels of ET-1, more vaso-
constriction, and lower blood flow, may be contributing to lower 
levels of macrophages (i.e., lower innate immune response) and po-
tentially to build-up of fluid in the lungs (pulmonary edema).
Our study has a number of strengths. The case-control design 
with cases from multiple hospitals and a large, prospective, popula-
tion-based control group with 98% coverage of the local population 
has provided the power needed to identify independent risk factors, 
including medication use, to assess the risk factors for COVID-19 
in this population. We have included consecutive cases from each of 
the secondary care hospitals to reflect the full range of case-mix seen 
in routine clinical practice. Case definition and assessment of sever-
ity of COVID-19 were adherent to national guidelines consistently 
across all the centers involved in this study.16
The limitations of our study include the retrospective nature of 
the COVID-19 cohort, which could lead to possible under-record-
ing of some less common comorbidities and drug history, in par-
ticular, related to use of glucocorticoids. Even though we included 
578 cases, we may have modest power to evaluate potential risk 
factors with low frequency. In the large case series (n = 1,099) of 
patients with COVID-19,3 a number of comorbidities, such as car-
diovascular (2.5%), cerebrovascular (1.4%), and chronic obstructive 
pulmonary diseases (1.1%) were infrequent, and cancers, immuno-
deficiency, and chronic kidney disease altogether formed 1.8% of 
the COVID-19 cases. Most patients with cardiovascular comorbid-
ities qualify for ACEI or ARB therapy. However, prescribing pat-
terns of these drugs vary widely from China to the United Kingdom 
where ACEIs are much more commonly prescribed.43 Although 
with a much larger sample size this may prove to be significant if the 
effect is real, this compared poorly with other factors contributing 
to severity, such as hypertension (OR 2.8) or the use of immunosup-
pressants (OR 5.37). In addition, the low case-fatality rate of 0.6% 
means that we were not able to assess risk factors associated with 
mortality. Another limitation is the lack of pre-pandemic data on 
glycemic control, since DPP4 inhibitors and insulin are usually pre-
scribed to patients with poorer glycemic control than those receiv-
ing glucosidase inhibitors. Therefore, differences in severity seen 
among these medication categories could be reflecting differences 
in glycemic control and not necessarily an effect of the medication 
on disease progression. Moreover, although all the medications in-
cluded corresponded to prescriptions filled 3 or more times before 
diagnosis of COVID-19, we were unable to adjust for length of 
use of the medications and the current analysis did not adjust for 
multiple testing so some of the more modest associations are viewed 
with caution. Finally, some of the associations show strong statistical 
significance but, as is the case for CCBs, the ORs are <  2.0 and, 
therefore, they may not be of high clinical impact.
CONCLUSION/CLINICAL RELEVANCE
We have identified higher BMI, diabetes, and cardiovascular, and 
cerebrovascular disease as independent risk factors for the devel-
opment of COVID-19. Prior treatment with ARBs and diuretics 
was associated with reduced risk and CCBs with increased risk 
of developing COVID-19. Other antihypertensive drugs were 
not associated with increased risk of severe or critical forms of the 
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infection. Therefore, we found no evidence to alter ARB or ACEI 
therapy in the context of the pandemic. We have also found for 
the first time, an increased risk of COVID-19 in association with 
DPP4 inhibitors and insulin as reduced risk with glucosidase in-
hibitors. If replicated, these findings have clinical and potentially 
public health implications.
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